The downgrade from Buy to Outperform is a slight negative as it suggests that the stock might not have as much upside potential as previously thought. However, the $610 price target implies a belief in continued growth, which could mitigate any negative impact from the downgrade. The net effect on the stock price is likely to be neutral in the short term.